NZ549393A - Methods for reducing oxidative damage - Google Patents

Methods for reducing oxidative damage

Info

Publication number
NZ549393A
NZ549393A NZ549393A NZ54939305A NZ549393A NZ 549393 A NZ549393 A NZ 549393A NZ 549393 A NZ549393 A NZ 549393A NZ 54939305 A NZ54939305 A NZ 54939305A NZ 549393 A NZ549393 A NZ 549393A
Authority
NZ
New Zealand
Prior art keywords
dmt
phe
arg
oxidative damage
methods
Prior art date
Application number
NZ549393A
Other languages
English (en)
Inventor
Hazel H Szeto
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Publication of NZ549393A publication Critical patent/NZ549393A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
NZ549393A 2004-01-23 2005-01-21 Methods for reducing oxidative damage NZ549393A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53884104P 2004-01-23 2004-01-23
PCT/US2005/002119 WO2005072295A2 (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage

Publications (1)

Publication Number Publication Date
NZ549393A true NZ549393A (en) 2009-07-31

Family

ID=34826019

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ549393A NZ549393A (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage

Country Status (13)

Country Link
US (8) US7550439B2 (cg-RX-API-DMAC7.html)
EP (1) EP1722807A4 (cg-RX-API-DMAC7.html)
JP (1) JP4931604B2 (cg-RX-API-DMAC7.html)
KR (1) KR101159254B1 (cg-RX-API-DMAC7.html)
CN (1) CN1938042B (cg-RX-API-DMAC7.html)
AU (1) AU2005208821B8 (cg-RX-API-DMAC7.html)
BR (1) BRPI0507053A (cg-RX-API-DMAC7.html)
CA (7) CA2971931C (cg-RX-API-DMAC7.html)
IL (5) IL177030A (cg-RX-API-DMAC7.html)
NZ (1) NZ549393A (cg-RX-API-DMAC7.html)
RU (1) RU2376028C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005072295A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200607013B (cg-RX-API-DMAC7.html)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1599216E (pt) 2003-02-04 2013-12-17 Cornell Res Foundation Inc Métodos de prevenção da transição de permeabilidade mitocondrial
DK2604285T3 (en) 2003-05-01 2014-12-01 Cornell Res Foundation Inc Method and carrier complex for delivering molecules to cells
CA2971931C (en) 2004-01-23 2019-01-08 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US8822542B2 (en) 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
GB0517090D0 (en) * 2005-08-19 2005-09-28 Tcp Innovations Ltd ApoE mimetic agents
EP3725324A1 (en) * 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
AU2014203126B2 (en) * 2005-09-16 2016-03-10 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
AU2019257440B2 (en) * 2005-09-16 2021-12-16 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
EP2054047B1 (en) 2006-07-25 2014-12-17 Hough Ear Institute Methods for treating acute acoustic trauma
WO2008094275A1 (en) * 2007-01-30 2008-08-07 New York University Peptides for treatment of conditions associated with nitric oxide
JP4461159B2 (ja) * 2007-06-14 2010-05-12 ヤマハファインテック株式会社 プリント基板の検査装置および検査方法
DK2252312T3 (da) * 2008-02-07 2014-06-16 Univ Cornell Fremgangsmåder til forebyggelse eller behandling af insulinresistens
CN101951936A (zh) 2008-02-26 2011-01-19 康奈尔大学 用于防止和治疗急性肾损伤的方法
DE102008061044A1 (de) 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
CN102573881A (zh) * 2009-03-20 2012-07-11 通用医疗公司以马萨诸塞州通用医疗公司名义经营 预防和治疗烧伤损伤和继发性并发症的方法
EP2477594A4 (en) * 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
JP5909182B2 (ja) * 2009-08-12 2016-04-26 コーネル ユニヴァーシティー 代謝性症候群を予防し又は治療するための方法
EP3338788A1 (en) 2009-08-24 2018-06-27 Stealth Peptides International, Inc. Methods and copositions for preventing or treating opthalmic conditions
CN102711785A (zh) * 2009-10-05 2012-10-03 康奈尔大学 预防或治疗心力衰竭的方法
EP3090754A1 (en) * 2009-12-31 2016-11-09 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
US20130190244A1 (en) * 2009-12-31 2013-07-25 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
CN104725472A (zh) * 2010-01-25 2015-06-24 康奈尔大学 芳香族阳离子肽及其用途
US20130040901A1 (en) * 2010-02-26 2013-02-14 University Of Florida Research Foundation Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3040080A1 (en) 2010-03-15 2016-07-06 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US20110245182A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245183A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
EP2942354A1 (en) * 2010-05-03 2015-11-11 Stealth Peptides International, Inc. Aromatic-Cationic Peptides and Uses of Same
HUP1000243A2 (en) 2010-05-06 2012-01-30 Avidin Kft 8-hidroxy-quinoline derivatives
US9345738B2 (en) * 2010-07-09 2016-05-24 Stealth Biotherapeutics Corp. Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
US20130288985A1 (en) * 2010-07-15 2013-10-31 The Schepens Eye Research Institute Inc. Compositions and methods of treatment of corneal endothelium disorders
JP6121904B2 (ja) 2010-09-08 2017-04-26 ハロザイム インコーポレイテッド 条件的活性治療用タンパク質を評価および同定する、または発展させる方法
US20120083452A1 (en) * 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
JP6099574B2 (ja) 2011-02-04 2017-03-22 ハフ イヤ インスティテュート 外傷性脳損傷を処置する方法
US20150118315A1 (en) * 2011-06-14 2015-04-30 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN102327600A (zh) * 2011-09-14 2012-01-25 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防和治疗辐射损伤的rx31肽
JP6157481B2 (ja) 2011-09-29 2017-07-05 メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ 芳香族陽イオン性ペプチドおよびその使用方法
CN104114181B (zh) * 2011-10-17 2017-06-09 康奈尔大学 芳香族阳离子肽及其用途
CA2865317A1 (en) 2012-02-22 2013-08-29 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
WO2013126775A1 (en) * 2012-02-23 2013-08-29 Cornell University Aromatic-cationic peptides and uses of same
WO2013134743A1 (en) 2012-03-08 2013-09-12 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
CA2869080C (en) * 2012-03-30 2020-09-01 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
DK2961378T3 (da) * 2013-03-01 2019-11-25 Stealth Biotherapeutics Corp Fremgangsmåder til behandlingen af mitochondrisk sygdom
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US9884085B2 (en) 2013-06-26 2018-02-06 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
CA2920020C (en) 2013-08-02 2023-03-14 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
JP6480921B2 (ja) * 2013-09-27 2019-03-13 コーネル ユニヴァーシティー コレステロール誘発性ミトコンドリア機能不全を治療するための芳香族カチオン性ペプチドの使用
US20160375088A1 (en) * 2013-09-30 2016-12-29 Brian Yinge ZHAO Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
US9982014B2 (en) 2013-10-23 2018-05-29 Kaneka Corporation Tetrapeptide compound and method for producing same
EP3077049B1 (en) * 2013-12-02 2019-06-19 Stealth BioTherapeutics Corp Compositions for use in treating vitiligo
WO2015095077A1 (en) * 2013-12-16 2015-06-25 Cornell University Methods and compositions for treating and preventing cognitive dysfunction
US10053490B2 (en) 2014-01-22 2018-08-21 Agency For Science, Technology And Research Antimicrobial peptidomimetics
US9314457B2 (en) 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases
HUE054626T2 (hu) 2014-06-25 2021-09-28 Flamma Spa Eljárás D-arginil-2,6-dimetil-L-tirozil-L-lizil-L-fenilalaninamid elõállítására
US10112976B2 (en) 2014-06-30 2018-10-30 Flamma S.P.A. Process for the production of D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
WO2016200364A1 (en) * 2015-06-08 2016-12-15 Stealth Peptides International, Inc. THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF
WO2017070421A1 (en) * 2015-10-22 2017-04-27 The Feinstein Institute For Medical Research Use of dermcidin in sterile inflammatory conditions
CA3006698A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
RU2613910C1 (ru) * 2015-12-08 2017-03-21 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ - ИМБП РАН) Способ определения тканевой гипоксии скелетных мышц и миокарда при гиподинамии
US20170224764A1 (en) * 2016-02-10 2017-08-10 Cornell University Therapeutic targeting of mitochondria to prevent osteoarthritis
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
CA3100943A1 (en) * 2018-05-23 2019-11-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cardiac-specific targeting-peptide (ctp), compositions, and uses thereof
WO2022011311A1 (en) * 2020-07-09 2022-01-13 Musc Foundation For Research Development Methods of protecting cells from insults
JP2023541403A (ja) 2020-09-09 2023-10-02 ソーシャル・プロフィット・ネットワーク ビオチンをミトコンドリアに送達するための方法及び組成物
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
CN114773433B (zh) * 2022-06-23 2022-09-06 北京肿瘤医院(北京大学肿瘤医院) 一种cd25靶向多肽、分子探针及应用
GB2630566A (en) * 2023-05-22 2024-12-04 Jaguar Land Rover Ltd Apparatus and method for controlling an actuator

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5312899A (en) 1988-06-30 1994-05-17 Biochem Pharma, Inc. Dermorphin analogs
US5118670A (en) * 1988-12-14 1992-06-02 Massachusetts Institute Of Technology Process and composition for increasing brain dopamine release
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
ATE255450T1 (de) * 1995-06-09 2003-12-15 Hisamitsu Pharmaceutical Co Matrix für iontophorese
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
ES2199353T3 (es) 1996-10-07 2004-02-16 Eli Lilly And Company Nuevos compuestos utiles como agentes neuro-protectores.
RU2115660C1 (ru) * 1997-01-28 1998-07-20 Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН Пептиды, обладающие антистрессорным, противосудорожным и нейропротекторным действием
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
EP1037911A4 (en) 1997-12-10 2003-07-23 Univ Washington ANTI-PATHOGEN SYSTEM AND METHOD FOR USE THEREOF
US6417210B1 (en) * 1998-01-09 2002-07-09 Mor-Research Applications Ltd. Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
AU3965699A (en) 1998-04-24 1999-11-16 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
WO2001025486A1 (en) 1999-10-04 2001-04-12 University Of Medicine And Dentistry Of New Jersey Methods for identifying rna binding compounds
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
EP1303186B1 (en) * 2000-07-18 2011-01-26 Cornell Research Foundation, Inc. Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
MXPA03004821A (es) 2000-11-28 2004-03-26 Guilford Pharm Inc Compuestos de union de ciclofilina carbociclica bisubstutuida y su uso.
EP1360173A2 (en) 2001-01-25 2003-11-12 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
US20030077826A1 (en) 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
PT1599216E (pt) 2003-02-04 2013-12-17 Cornell Res Foundation Inc Métodos de prevenção da transição de permeabilidade mitocondrial
DK2604285T3 (en) 2003-05-01 2014-12-01 Cornell Res Foundation Inc Method and carrier complex for delivering molecules to cells
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
CA2971931C (en) * 2004-01-23 2019-01-08 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP3725324A1 (en) 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression

Also Published As

Publication number Publication date
AU2005208821B8 (en) 2010-10-14
US20140349942A1 (en) 2014-11-27
CA3024434A1 (en) 2005-08-11
US7781405B2 (en) 2010-08-24
JP4931604B2 (ja) 2012-05-16
AU2005208821A1 (en) 2005-08-11
IL177030A (en) 2015-04-30
US7550439B2 (en) 2009-06-23
CN1938042B (zh) 2010-06-02
RU2006130431A (ru) 2008-02-27
IL237408A0 (en) 2015-04-30
AU2005208821B2 (en) 2010-09-30
WO2005072295A3 (en) 2005-09-29
CA2971929A1 (en) 2005-08-11
CN1938042A (zh) 2007-03-28
CA2971929C (en) 2019-01-08
CA2851972C (en) 2015-06-23
US9950026B2 (en) 2018-04-24
AU2005208821A2 (en) 2005-08-11
IL237408B (en) 2019-03-31
CA2554166A1 (en) 2005-08-11
CA2887797A1 (en) 2005-08-11
IL237407B (en) 2018-07-31
KR101159254B1 (ko) 2012-06-26
CA2554166C (en) 2014-07-29
KR20070003872A (ko) 2007-01-05
RU2376028C2 (ru) 2009-12-20
US20060084606A1 (en) 2006-04-20
US20190328821A1 (en) 2019-10-31
US20070015711A1 (en) 2007-01-18
ZA200607013B (en) 2008-01-08
CA2971928C (en) 2019-01-08
US9623069B2 (en) 2017-04-18
CA2851972A1 (en) 2005-08-11
US20160317604A1 (en) 2016-11-03
US8618061B2 (en) 2013-12-31
CA2971931A1 (en) 2005-08-11
IL256703A (en) 2018-03-29
US20100311664A1 (en) 2010-12-09
US20210015887A1 (en) 2021-01-21
CA2971928A1 (en) 2005-08-11
CA2971931C (en) 2019-01-08
EP1722807A4 (en) 2010-09-15
BRPI0507053A (pt) 2007-06-12
CA2887797C (en) 2017-09-26
IL177030A0 (en) 2006-12-10
HK1102289A1 (zh) 2007-11-16
EP1722807A2 (en) 2006-11-22
IL235772A (en) 2016-12-29
WO2005072295A2 (en) 2005-08-11
IL256703B (en) 2020-11-30
US20230149501A1 (en) 2023-05-18
JP2007518818A (ja) 2007-07-12
IL237407A0 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
NZ549393A (en) Methods for reducing oxidative damage
WO2006125227A3 (en) Fibroblast activation protein inhibitor compounds and methods
EP2628749A3 (en) Antimicrobial kinocidin compostions and methods of use
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
WO2002018369A3 (en) Peptidomimetic protease inhibitors
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
WO2004043382A3 (en) Enhanced variants of erythropoietin and methods of use
ITMI20042393A1 (it) Procedimento per la fabbricazione di un componente a semiconduttore nonche' un componente a semiconduttore in particolare un sensore a membrana
WO2005020880A3 (en) Methods for the treatment of endometriosis
AP2001002291A0 (en) Novel method of treatment.
WO2003030886A3 (en) Allylamides useful in the treatment of alzheimer's disease
IL158385A0 (en) Modified cyclosporin which can be used as a pro-drug and use thereof
ATE465725T1 (de) Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
WO2000047547A3 (en) Cycloalkyl amine compounds and uses thereof
WO2004041213A3 (en) Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein
EP1514551A4 (en) ANTI-INFLAMMATORY, AGENT TO COMBAT ALLERGIC DISEASES, AND FUNCTIONAL FOOD
MXPA03011399A (es) Metodos para tratar la enfermedad de alzheimer.
WO1999043308A3 (en) Treating pulmonary hypertension through tenascin suppression and elastase inhibition
WO2003033024A1 (fr) Inhibiteur de proliferation cellulaire
USD858771S1 (en) Apparatus for treating body tissue sphincter
DE50102739D1 (en) Arzneimittel enthaltend tissue inhibitor of metalloproteinases-2 (timp-2) als osteoanabol wirksame substanz
AU4584100A (en) Morphinoid compounds
ATE418998T1 (de) Verwendung von barusiban zur herstellung eines medikaments zur behandlung von hypertonie bei schwangerschaft
WO2004100849A3 (en) A burial casket

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2016 BY COMPUTER PACKAGES INC

Effective date: 20141231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2017 BY COMPUTER PACKAGES INC

Effective date: 20151231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2018 BY COMPUTER PACKAGES INC

Effective date: 20161231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2019 BY COMPUTER PACKAGES INC

Effective date: 20180103

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2020 BY COMPUTER PACKAGES INC

Effective date: 20190101

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2021 BY COMPUTER PACKAGES INC

Effective date: 20191231

LAPS Patent lapsed